Conviction
$ Value
$3K
Shares
2,000
Price
$2
Filed
Jun 26
▶ Why this score? (9/10)
- ✓ Open market buy (+3)
- ✓ % of holdings >= 50% (+3)
- ✓ C-suite insider (+2)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
Bardin Stephen
Title
Chief Financial Officer
CIK
0001942596
Roles
Transaction Details
Transaction Date
2025-06-26
Code
P
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
3,000
Footnotes
The weighted average purchase price for the transaction reported was $1.5025, and the range of prices were between $1.45 and $1.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. | Includes 1,000 shares held by The Bardin Family Trust dated June 4, 2024 (the "Trust") which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025. | By The Bardin Family Trust dated June 4, 2024. | Excludes 1,000 shares held by the Trust which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025. | The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. | Immediately exercisable.
Filing Info
Bardin Stephen's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-06-26 | CALC | ▲ | $3K ★ |
| 2025-06-24 | CALC | A | $0 |
| 2025-05-30 | CALC | ▲ | $2K |
| 2025-04-23 | CALC | A | $0 |
| 2025-04-05 | CALC | A | $0 |
Other Insiders at CALC (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Leheny A. Rachel
CHIEF EXECUTIVE OFFICER
|
— | — | 2025-04-05 |
|
Roberts Eric W
CHIEF BUSINESS OFFICER
|
— | — | 2025-04-05 |
|
Bardin Stephen
Chief Financial Officer
|
— | — | 2025-04-05 |
|
Dunn Michael J.
President and COO
|
— | — | 2025-04-05 |
|
Hebbar Sudarshan
Chief Medical Officer
|
— | — | 2025-04-05 |
|
Stauderman Kenneth A.
Chief Scientific Officer
|
— | — | 2025-04-05 |